Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Hepatocellular Carcinoma (HCC) Clinical Trials

16 recruiting trials for Hepatocellular Carcinoma (HCC). Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
16
Total Trials
16
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT06636435

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors,...

In this first-in-human, muticenter, non-randomized, open-label, standard 3+3 dose escalation Phase I study encompasses 5 parts (Part 1-5). The purpose of this FIH study is to...

Sponsor: Chiome Bioscience Inc.Enrolling: 665 locations
RECRUITINGPhase 1 / Phase 2NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with...

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional...

Sponsor: GI Innovation, Inc.Enrolling: 35811 locations
RECRUITINGNCT06653062

Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance

This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a...

Sponsor: Tongji HospitalEnrolling: 501 location
RECRUITINGNCT07365930

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS)...

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestEnrolling: 3501 location
RECRUITINGEarly Phase 1NCT06652243

Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma

This is a single-arm, open-label study of safety, tolerability, and anti-cancer activity of SN301A (an off-the-shelf CAR NK cell therapy) in patients with glypican-3...

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEnrolling: 121 location
RECRUITINGPhase 2NCT06860490

HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

To evaluate HAIC combined with Sintilimab plus bevacizumab biosimilar for advanced hepatocellular carcinoma.

Sponsor: Fudan UniversityEnrolling: 1641 location
RECRUITINGPhase 1NCT06689540

Mts105 for Advanced Hepatocellular Carcinoma

This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced...

Sponsor: Shen LinEnrolling: 141 location
RECRUITINGNCT07291141

A Comparative Study of MRI and Ultrasound for Detection of Primary Hepatocellular Carcinoma, Body Composition and Risk...

DETECT-HCC-ESLD is a prospective multicenter study designed to examine early detection and risk stratification of hepatocellular carcinoma (HCC) in individuals with advanced liver...

Sponsor: Mattias EkstedtEnrolling: 6001 location
RECRUITINGPhase 1NCT07419841

A Phase 1 Study of the Safety and Tolerability of CTX-10726

This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2...

Sponsor: Compass TherapeuticsEnrolling: 702 locations
RECRUITINGNCT06999174

Multiparametric MRI for Characterization of Hepatocellular Carcinoma

This prospective observational study investigates using multiparametric magnetic resonance imaging (MRI) to improve the characterization and management of therapy for...

Sponsor: University Hospital MuensterEnrolling: 1281 location
RECRUITINGPhase 4NCT07150624

The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine

A multicenter, open-label, randomized, controlled study. It is proposed to evaluate the treatment plan of receiving 930mg polyene phosphatidylcholine injection one day before the...

Sponsor: Anhui Provincial HospitalEnrolling: 961 location
RECRUITINGPhase 2NCT06762782

Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk...

This study is a prospective, randomized, controlled, open, phase II, multicenter clinical study, which aims to evaluate the efficacy and safety of lenvatinib for adjuvant...

Sponsor: The First Affiliated Hospital with Nanjing Medical UniversityEnrolling: 2761 location
RECRUITINGPhase 2NCT07337460

Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors

This is a single-center, single-arm, prospective trial to explore the efficacy and safety of Icaritin Soft Capsules combined with postoperative adjuvant hepatic arterial infusion...

Sponsor: Northern Jiangsu People's HospitalEnrolling: 301 location
RECRUITINGEarly Phase 1NCT04601428

Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy. IA therapy takes advantage of...

Sponsor: Koo Foundation Sun Yat-Sen Cancer CenterEnrolling: 434 locations
RECRUITINGPhase 1 / Phase 2NCT06725121

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

The goal of this clinical trial is to learn if locoregional therapy and immunotherapy can be used together to help patients with hepatocellular carcinoma (HCC) and macrovascular...

Sponsor: University Health Network, TorontoEnrolling: 482 locations
RECRUITINGPhase 1NCT07369505

Sapu003 in Advanced mTOR-sensitive Solid Tumors

This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced...

Sponsor: SAPU NANO (US) LLCEnrolling: 271 location